MannKind Corporation
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| MNKD | FTRE | SLDB | MAZE | DSGN | LXRX | |
|---|---|---|---|---|---|---|
| Market cap | 1.26B | 2.01B | 699.11M | 1.85B | 665.24M | 658.53M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | 29.1 | 18.6 | -3.8 | -10.5 | -6.6 | -7.8 |
| Price/book | -18.1 | 3.8 | 2.9 | 4.1 | 3.0 | 3.8 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −38.45% | +75.31% | +59.80% | +6.54% | +57.86% | +5.80% |
| Today | +5.36% | −0.57% | +3.82% | +3.50% | +2.80% | +1.37% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All MNKD news ›MannKind’s IPF inhalation medical treatment passes Phase 1b
Pamela Brown is the founder of PMB Writing, providing editorial and marketing services to small and large businesses. She has worked as a journalist for over 30 years, with a writing portfolio that spans magazines, newspapers, digital…
Analysts Are Bullish on Top Healthcare Stocks: Xencor (XNCR), MannKind (MNKD)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Xencor (XNCR), MannKind (MNKD) and Eikon Therapeutics, Inc. (EIKN) with bullish sentiments. Wells Fargo analyst Derek Archila maintained a Buy…
Chardan Capital Initiates Coverage on MannKind (NASDAQ:MNKD)
Investment analysts at Chardan Capital started coverage on shares of MannKind (NASDAQ:MNKD – Get Free Report) in a research note issued to investors on Monday, Benzinga reports. The brokerage set a “buy” rating and a $10.00 price target on…
MannKind to Participate in the Chardan Healthcare Conference
QTREX Quantum Announces Clean Capital Structure MannKind (Nasdaq: MNKD) announced that CEO Michael Castagna will participate in a Chardan Healthcare Conference panel on October 20, 2026. DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Oct.…
MannKind CEO to join panel on chronic respiratory disease innovation at Chardan Healthcare Conference
MannKind Corporation announced that CEO Michael Castagna will participate in a panel on innovation in chronic respiratory diseases at the Chardan Healthcare Conference on October 20, 2026. The panel will focus on diseases like idiopathic…
MannKind Stock Plummets After Partner United Therapeutics Unveils New ‘Category Killer Product’
Shares of MannKind Corp. (MNKD) slipped 38% on Wednesday after its partner United Therapeutics Corp. (UTHR) unveiled a new product called Tresmi, which could potentially replace the Tyvaso DPI dry powder inhaler it manufactures. Tresmi, as…
MannKind Data at HFSA 2026 Highlights New Evidence Supporting Furoscix ReadyFlow™ for the Outpatient Management of Edema in Heart Failure (HF) and Chronic Kidney Disease (CKD)
Building on the Recent Approval and Launch of Furoscix ReadyFlow Visit MannKind at HFSA ASM 2026 MannKind’s commercial and medical affairs teams will be available at booth 428 throughout HFSA 2026 to discuss Furoscix and how it may support…
MannKind Presents New Data Showing Furoscix ReadyFlow Delivers IV-Equivalent Diuresis Across Injection Sites at HFSA 2026
Furoscix ReadyFlow demonstrates comparable diuretic effects to IV furosemide, offering flexible outpatient treatment for heart failure and CKD. Furoscix ReadyFlow is an autoinjector delivering furosemide for treating fluid overload in…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- defenseworld.net1
- globenewswire.com1
- markets.businessinsider.com1
- pluang.com1
- quiverquant.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 7 articles, not a forecast.